Tamoxifen Resistance and CYP2D6 Copy Numbers in Breast Cancer Patients

  • Motamedi, Sahar (Science and Research Tehran Branch of Islamic Azad University) ;
  • Majidzadeh, Keivan (Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR)) ;
  • Mazaheri, Mahta (Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR)) ;
  • Anbiaie, Robab (Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR)) ;
  • Mortazavizadeh, Seyed Mohammad Reza (Department of Oncology and Hematology, Shahid Sadoughi University of Medical Sciences) ;
  • Esmaeili, Rezvan (Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR))
  • Published : 2012.12.31


Background: Breast cancer accounts about one million from total annual ten million new diagnosed cases of neoplasia worldwide and is the main cause of death due to cancer in women. Tamoxifen is the most popular selective estrogen receptor modulator used in anti estrogen treatments. Tamoxifen must be converted into its metabolite endoxifen for biologic effects; this conversion process is catalysed by highly polymorphic cytochrome P450 2D6 (CYP2D6). This study surveyed copy number variation of the CYP2D6 gene and its possible correlation with Tamoxifen resistance in breast cancer patients. Methods: This case control study was performed on samples taken from 79 patients with breast cancer who used tamoxifen in Yazd and Tehran Cities, Iran. Real time reactions were conducted for 10 healthy samples using the comparative $C_t$ (Cycles threshold) method, each pair of genes being compared and samples with ratios around 1 were taken as control samples. Proliferation reactions were done by Real-Time PCR ABI Prism 7500. All registered data were transformed into SPSS 15 program and analyzed. Results: Efficiency of PCR for both CYP2D6 and ALB genes was 100%. From all 23 drug resistant patients 21.7% had one copy, 47.8% two copies and 30.4% had three copies. Also from all 56 drug sensitive patients, 26.8% had one copy, 51.8% two copies and 21.4% had three copies. The percentage of patients with one and two copies was similar between two groups but patients with three copies were more likely to belong to the drug resistant group more. Odd ratios for one and two copies were 0.759 and 0.853 respectively, indicating possible protective effects while that for three copies was 1.604. Conclusions: Based on our study there is no significant link between CYP2D6 gene copy numbers and tamoxifen resistance in women with breast cancer. But more studies considering other influencing factors appear warranted.


Tamoxifen;CYP2D6 gene;copy numbers;drug resistance


  1. National cancer institute. US department of health and human services. Breast cancer booklet:What you need to know about Breast cancer (2009). NIH publication. Rockville, Maryland, USA.
  2. Nguyen DL, Staeker J, Laika B, Steimer W (2009). TaqMan real-time PCR quantification strategy of CYP2D6 gene copy number for the LightCycler 2.0. Clinica Chim Acta, 403, 207-11.
  3. Okishiro M, Taguchi T, Jin KS, et al (2009). Genetic polymorphisms of CYP2D610 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 115, 952-61.
  4. Okishiro SA, Ahn J, Rae JM, et al (2005). Association of genetic variation in tamoxifen metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat, 91, 249-58.
  5. Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med, 339, 1609-18.
  6. Ozawa S, Soyama A, Saeki M, et al (2004). Ethnic differences in genetic polymorphisms ofCYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet, 19, 83-95.
  7. Park IH, Ro J, Park S, et al (2011). Association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat, 131, 455-61.
  8. Pulczynska A, Lukaszkiewicz J, Wojnar M, et al (2011). Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication. Acta Pol Pharm, 68, 9-13.
  9. Sebat J, Lakshmi B, Troge J, et al (2004). Large-scale copy number polymorphism in the human genome. Sci, 305, 525-8.
  10. Schaeffeler E, Schwab M, Eichelbaum M, et al (2003). CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat, 22, 476-85.
  11. Torresan C, Oliveira MMC, Torrezan GT, et al (2008). Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med, 8, 65-71.
  12. Wegman P, Elingarami S, Carstensen J, et al (2007). Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res, 9, 7.
  13. Wegman P, Elingarami S, Carstensen J, et al (2005). Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res, 7, 284-90.
  14. Wu X, Hawse JR, Subramaniam M, et al (2009). The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor ${\alpha}$ for degradation in breast cancer cells. Cancer Re, 69, 1722-27.
  15. Yu KD, Shao ZM (2009). Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nature. Nat Rev Cancer, 9, 842.
  16. Bodin L, Beaune PH, Loriot MA (2005). Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol, 3, 248-53.
  17. Bonanni B, Macis D, Maisonneuve P, et al (2006). Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian tamoxifen trial. J Clin Oncol, 24, 3708-9.
  18. Bradford LD (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3, 229-43.
  19. Gjerde J, Hauglid M, Breilid H, et al (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol, 19, 56-61.
  20. Goetz MP, Rae JM, Suman VJ, et al (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol, 23, 9312-8.
  21. Hoskins JM, Carey LA, McLeod HL (2009). CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature, 9, 576-86.
  22. Hosono N, Kato M, Kiyotani K, et al (2009). CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clinical Chemistry, 55, 1546-54.
  23. Ingelman-Sundberg M (1991). Duplication multiduplication and amplification of gene encoding drug-metabolizing enzyme, evolutionary, toxicological and pharmacological aspects. Drug Metab Rev, 31, 449-59.
  24. Ingelman-Sundberg M, SimSC, Gomez A, et al (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther, 116, 496-526.
  25. Janelle M, Hoskins S, Lisa A, et al(2009). CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature reviews, 9, 576-86.
  26. Johansson I, Lundqvist E, Bertilsson L, et al (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA, 90, 11825-9.
  27. Kirchheiner J, Henckel HB, Franke L, et al (2005). Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics, 15, 579-87.
  28. Lim HS, Ju Lee H, Seok LK, et al (2007). Clinical implications of CYP2D6 genotypes of predictive tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol, 25, 3837-45.
  29. Lundqvist E, Johansson I, Ingelman-Sundberg M (1999). Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene, 226, 327-38.
  30. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Annals of Oncology, 20, 556-63,

Cited by

  1. Plasma proteomics analysis of tamoxifen resistance in breast cancer vol.30, pp.4, 2013,
  2. Correlation of Tumour Response with Starting Tumour Size and Dose of Tamoxifen in an N-Methyl-N-Nitrosourea (NMU)-Induced Rat Mammary Cancer Model vol.15, pp.16, 2014,
  3. Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials vol.15, pp.5, 2014,
  4. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients vol.16, pp.15, 2015,
  5. CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence vol.5, pp.5, 2016,
  6. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer vol.17, pp.4, 2017,
  7. A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen vol.8, pp.1, 2018,